Winselow Tucker, Eli Lilly's new Loxo unit chief commercial officer

Eli Lil­ly plucks a new com­mer­cial chief from Bris­tol My­ers in man­age­ment shuf­fle as HR chief re­tires

Eli Lil­ly has found a new chief com­mer­cial of­fi­cer from among the ranks at Bris­tol My­ers Squibb, as it says farewell to its long­time head of hu­man re­sources Stephen Fry.

Stephen Fry

Fry an­nounced on Thurs­day his plans to re­tire af­ter more than 35 years with Lil­ly. He’ll va­cate his seat as SVP of hu­man re­sources and di­ver­si­ty at the end of the year, and cur­rent Loxo CCO Er­ic Dozi­er is slat­ed to take his place. As a re­sult, BMS’ Win­selow Tuck­er is join­ing the team as Loxo CCO at the end of the month.

Tuck­er is leav­ing his post as in­ter­con­ti­nen­tal SVP at BMS, a job he’s held for on­ly about eight months. Be­fore that, he was the SVP and gen­er­al man­ag­er of the hema­tol­ogy busi­ness, where, among oth­er ac­com­plish­ments, he was one of the lead­ers be­hind the phar­ma gi­ant’s $300 mil­lion com­mit­ment to com­bat racial dis­par­i­ties.

Er­ic Dozi­er

“What I’m re­al­ly ex­cit­ed about is that this is a tan­gi­ble view,” he told End­points News back in 2020, “that we’re not just look­ing ex­ter­nal­ly, we’re al­so look­ing in­ter­nal­ly as well to fig­ure out how can we sup­port the right eq­ui­ty across both our in­ter­nal or­ga­ni­za­tions and in the com­mu­ni­ties of pa­tients that we serve.”

Tuck­er has been vo­cal about ad­dress­ing racial dis­par­i­ties with­in health­care and was al­so in­volved in BMS’ Stand­ing in the Gaap pro­gram de­signed to close gaps in the di­ag­no­sis, care and sur­vival rates of African Amer­i­cans with mul­ti­ple myelo­ma.

“I grew up in New York City, a city of con­trasts. I saw this first-hand when it came to in­for­ma­tion, ed­u­ca­tion, and op­por­tu­ni­ties. That aware­ness shaped who I am to­day and how I see and un­der­stand the world. I know that ac­cess to health­care and med­i­cines can change some­one’s life,” he wrote in a LinkedIn post mark­ing his 100th day as BMS’ in­ter­con­ti­nen­tal SVP.

Tuck­er added that he was ready to tran­si­tion from “the ini­tial pe­ri­od of lis­ten­ing and learn­ing to lean in­to our goals with full force.”

Ja­cob van Naar­den

“Win­selow brings deep ex­per­tise in both on­col­o­gy and hema­tol­ogy that will sup­port the con­tin­ued growth of our ex­ist­ing com­mer­cial port­fo­lio and ef­forts to bring our pipeline of can­cer med­i­cines to pa­tients around the world,” Ja­cob Van Naar­den, SVP and CEO Lil­ly’s Loxo unit, said in a news re­lease.

Fry is head­ing in­to re­tire­ment af­ter more than 35 years at Eli Lil­ly, where he start­ed as a sys­tems an­a­lyst in In­di­ana back in 1987, ac­cord­ing to his LinkedIn pro­file. Fry’s po­si­tions have spanned the globe, in­clud­ing HR di­rec­tor in the UK and gen­er­al man­ag­er in Aus­tralia and New Zealand.

Dave Ricks

“Steve has left a pos­i­tive and in­deli­ble im­print on the peo­ple, cul­ture and per­for­mance of our com­pa­ny,” CEO David Ricks said in a news re­lease. “Serv­ing as our CHRO over the past 11 years, Steve has played a key role in lead­ing us through the chal­lenges we faced in those ear­ly years, mod­ern­iz­ing so many di­men­sions of our HR func­tion—in­clud­ing di­ver­si­ty, eq­ui­ty and in­clu­sion—and lead­ing the com­pa­ny’s ef­forts to be­come a pre­mier em­ploy­er around the world.”

That leaves Dozi­er with some big shoes to fill, though Ricks is con­fi­dent he’s up for the task. Dozi­er has been with Lil­ly for near­ly 25 years, hop­ping from roles such as chief mar­ket­ing of­fi­cer for Japan to VP of glob­al ethics and com­pli­ance be­fore set­tling in as Loxo CCO.

“Er­ic is the right leader to dri­ve our peo­ple strat­e­gy and di­ver­si­ty, eq­ui­ty, and in­clu­sion agen­da as Lil­ly en­ters a new and ex­cit­ing chap­ter of growth,” Ricks said.

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

No­vo Nordisk re­mains un­der UK scruti­ny as MHRA con­ducts its own re­view in 'in­cred­i­bly rare' case

The UK’s Medicines and Healthcare products Regulatory Agency is now reviewing Novo Nordisk’s marketing violation that resulted in its loss of UK trade group membership last week. Novo Nordisk was suspended on Thursday from the Association of the British Pharmaceutical Industry (ABPI) for two years after an investigation by its regulatory arm found the pharma broke its conduct rules.

MHRA said on Tuesday that its review of the Prescription Medicines Code of Practice Authority (PMCPA) investigation is standard practice. An MHRA spokesperson emphasized in an email to Endpoints News that the situation with Novo Nordisk is “incredibly rare” while also noting ABPI took “swift and proportionate action.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

FTC says patent bat­tle over Parkin­son's drug could have 'sig­nif­i­cant im­pli­ca­tion­s' for pa­tients

The Federal Trade Commission has gotten involved in a patent feud over Supernus’ Parkinson’s drug Apokyn, a case the agency said may have ‘‘significant implications” for patients who rely on the drug.

Sage Chemical won the first generic approval for its Apokyn formulation (also known as apomorphine hydrochloride injection) back in 2022. The non-ergoline dopamine agonist is approved to treat Parkinson’s symptoms during “off episodes,” such as difficulty moving, tremors and intense cramping. However, regulators specified that the approval pertained to the generic drug cartridges only, not the injector pen required for administration.

Growth hor­mone from No­vo Nordisk is in short­age over man­u­fac­tur­ing de­lays

Novo Nordisk’s growth hormone Norditropin is in shortage because of manufacturing delays, according to an FDA site that tracks drug shortages as well as the American Society of Health-System Pharmacists’ shortages list.

The FDA has shortages of the drug listed for its 5, 10, 15 and 30 mg doses, while the pharmacists’ group, also known as ASHP, reported shortages of the same doses, except for the 15 mg version.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

PhRMA calls for more di­verse in­fra­struc­ture up­grades to US emer­gency tri­als frame­work

The White House’s Office of Science and Technology Policy (OSTP) last year sought to find ways to better coordinate large-scale clinical trials in the US — as the UK lead by example during the pandemic — especially for these emergency clinical trials.

The lobbying group PhRMA Tuesday called for more clinical trial diversity in underserved areas, including by making participation less of a burden, and expanding eligibility criteria when appropriate.

Mar­ket­ingRx roundup: What could a US Tik­Tok ban mean for phar­ma? Pfiz­er, Lil­ly lead phar­ma March Mad­ness ad­ver­tis­ers

Just as pharma marketers finally make moves into TikTok, the threat of a US ban on the social media channel is now looming. Already banned on federal employee phones by an initial Congressional act, more bills and maybe bans are on the way. With rare bipartisan agreement, lawmakers have introduced legislation that would give the US president the power to ban TikTok (although not mentioned by name) and other foreign-owned technology platforms that represent a security threat to the US.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Chat­G­PT with phar­ma da­ta de­buts for med­ical meet­ings, be­gin­ning with AACR

What do you get when you combine ChatGPT generative AI technology with specific pharma and clinical datasets? A time-saving tool that can answer questions about medical conference abstracts and clinical findings in seconds in one new application from ZoomRx called FermaGPT.

ZoomRx is debuting a public version of its generative AI product specifically for medical conferences beginning this week for the upcoming American Association for Cancer Research (AACR) annual meeting that runs April 14-19.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Who are the women break­ing bar­ri­ers in drug de­vel­op­ment? Nom­i­nate them for End­points' an­nu­al re­port

Today, we’re opening nominations for our fifth annual Women in Biopharma R&D special report.

Over the last four years, we’ve honored 80 women whose extraordinary accomplishments have changed the game in biopharma R&D. We’re looking for big thinkers, scientists, executives and other enterprising women who are breaking barriers in drug development and inspiring the next generation of leaders.

Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)

What kind of PhI­Ib da­ta is worth $4B cash? Take­da’s Andy Plump has some thoughts on that

A few months back, when Takeda caused jaws to drop with its eye-watering $4 billion cash upfront for a mid-stage TYK2 drug from Nimbus, it had already taken a deep dive on the solid Phase IIb data Nimbus had assembled from its dose-ranging study in psoriasis.

Now, it’s rolling that data out, eager to demonstrate what inspired the global biopharma to go long in a neighboring, but new, disease arena for the pipeline. And the most avid students of the numbers will likely be at Bristol Myers Squibb, who will have a multi-year head start on pioneering the TYK2 space with Sotyktu (deucravacitinib) as Takeda makes its lunge for best-in-class status.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.